<DOC>
	<DOCNO>NCT00243945</DOCNO>
	<brief_summary>The objective trial ass effect rotigotine ( SPM 962 ) control early morning motor impairment sleep disorder subject idiopathic PD . Subjects meet eligibility criterion begin treatment rotigotine transdermal patch . Trial medication titrate optimal daily dose , maximal dose . Following Titration period 8 week , subject maintain optimal maximal dose 4 week . After Maintenance period , subject option enter open-label extension study . The first subject enrol December 2004 . The last subject enrol April 2005 last subject visit conduct July 2005 . This study close</brief_summary>
	<brief_title>A Trial Evaluate Effects Rotigotine Transdermal Patch Early Morning Motor Impairment Sleep Disorders Idiopathic Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Idiopathic Parkinson 's disease Subject previously participate trial rotigotine . Subject participate another trial investigational drug within last 28 day currently participate another trial investigational drug . Subject discontinue previous therapy dopamine agonist adequate length treatment adequate dose due lack efficacy assess investigator . Subject prior therapy dopamine agonist within 28 day prior Baseline . Subject receive therapy controlledrelease levodopa within 28 day prior baseline receive therapy tolcapone . Subject receive therapy one follow drug either concurrently within 28 day prior Visit 2 : alphamethyl dopa , metoclopramide , reserpine , neuroleptic ( include atypical ) , monoamine oxidase A ( MAOA ) inhibitor , methylphenidate , amphetamine . Subject history symptomatic ( asymptomatic ) orthostatic hypotension 6 month prior baseline . Subject atypical Parkinsonian syndrome ( include druginduced Parkinsonian syndrome ) . Subject history atopic eczema and/or active skin disease , atopic eczema . Presence dementia , active psychosis , hallucination ( due antiparkinsonian medication ) . Subject receive CNS therapy ( eg , sedative , hypnotic , selective serotonin reuptake inhibitor [ SSRIs ] , anxiolytic , sleepmodifying medication ) unless dose stable daily least 28 day prior baseline likely remain stable duration trial . Subject history seizure stroke within 1 year , history myocardial infarction within last 6 month prior enrollment . Subject neoplastic disease require therapy within 12 month prior enrollment . Presence clinically relevant hepatic dysfunction . Presence clinically relevant renal dysfunction . Evidence clinically relevant cardiovascular disorder . Subject QTcB interval Â³500msec Screening Baseline ( Visit 1 2 ; repeat measurement within 1 hour ) . Subject history chronic alcohol drug abuse within last 6 month . Subject clinically significant laboratory result , opinion investigator , would make subject unsuitable entry trial . Subject pregnant nursing , child bear potential ( ) surgically sterile , , ( ii ) use adequate birth control method ( include least one barrier method ) , ( iii ) sexually abstinent , ( iv ) subject least two year post menopausal . Subject medical psychiatric condition , opinion investigator , jeopardize would compromise subject 's ability participate trial . Subject know hypersensitivity component trial medication state protocol . Subject previous diagnosis narcolepsy , sleep apnea syndrome , rapid eye movement ( REM ) behavior disorder , restless legs syndrome , periodic limb movement disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>